New pharmacotherapies for alcohol dependence: are they being used and what do they cost?

Christopher M Doran,* Julia E Fawcett,† Anthony P Shakeshaft,‡ Marian D Shanahan,§ Richard P Mattick¶

National Drug and Alcohol Research Centre, University of New South Wales, NSW 2052.

Correspondence: C.Doran@unsw.edu.au

1. Hall W, Teeson M, Lynsky M, Degenhardt L. The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-Being. Addiction 1999; 94: 1541-1550.
2. Mattick RP, Jarvis T. An outline for the management of alcohol problems: Quality Assurance in the Treatment of Drug Dependence Project. Canberra: Commonwealth Department of Human Services and Health, 1993. (Monograph no. 20.)
3. Health Insurance Commission. Pharmaceutical benefits schedule items statistics. Available at: www.hic.gov.au/statistics/dyn_pbs/forms/pbs_tab1.shtml (accessed Apr 2003).
4. MIMS Australia. MIMS annual. 26th ed. Sydney: Medi Media Australia, 2002.
5. Australian Department of Health and Ageing. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners. Canberra: The Department, 2001.
6. Australian Department of Health and Ageing. Medicare statistics. March quarter 2003. Table B6. Average patient contribution per service (patient and bulk billed services out-of-hospital only). Available at: www.health.gov.au/haf/medstats/index.pdf (accessed Jul 2003).

Online responses are no longer available. Please refer to our instructions for authors page for more information.